This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, T. K. H. Articles by Waxman, D. J. Search for Related Content PubMed PubMed Citation Articles by Chang, T. K. H. Articles by Waxman, D. J.

Enhanced Cyclophosphamide and Ifosfamide Activation in Primary Human Hepatocyte Cultures: Response to Cytochrome P-450 Inducers and Autoinduction by Oxazaphosphorines¹

Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215 [T. K. H. C., L. Y., D. J. W.]; Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, V6T 1Z3 Canada [T. K. H. C.]; and INSERM U-128, Centre National de la Recherche Scientifique, 34033 Montpellier, France [P. M.]

The anticancer oxazaphosphorine prodrugs cyclophosphamide and ifosfamide are activated in human liver by a 4-hydroxylation reaction catalyzed by multiple cytochrome P450 (CYP) enzymes. In the present study, we used a cultured human hepatocyte model to identify possible inducers of the CYP-catalyzed activation of these two anticancer prodrugs. Treatment of primary cultures of human hepatocytes with phenobarbital, dexamethasone, or rifampin elevated hepatocyte microsomal oxazaphosphorine 4-hydroxylation by up to 200–400% of control for both drug substrates. These inductions were associated with corresponding increases in immunoreactive CYP2B6, CYP2C8, CYP2C9, and CYP3A4, all previously shown to catalyze oxazaphosphorine activation. Rifampin (1 µM, 96-h exposure) was a particularly potent inducer of ifosfamide and cyclophosphamide 4-hydroxylation, as well as of CYP3A protein levels and CYP3A-dependent testosterone 6ß-hydroxylation. CYP3A4, CYP2C8, and CYP2C9 protein levels were also increased by exposure of the hepatocytes to cyclophosphamide or ifosfamide (50 µM), which thereby enhanced their own rates of 4-hydroxylation in the cultured hepatocytes. In one human hepatocyte culture that contained the polymorphically expressed CYP3A5 in addition to the more widely expressed CYP3A4, only CYP3A4 was induced by cyclophosphamide, ifosfamide, and rifampin. These studies: (a) demonstrate an underlying metabolic basis for the clinically important oxazaphosphorine autoinduction pharmacokinetics seen with these drugs in cancer patients; and (b) identify rifampin and other CYP inducers as potentially useful for increasing the rates of cyclophosphamide 4-hydroxylation and ifosfamide 4-hydroxylation in human liver in a manner that could favorably impact the clinical pharmacokinetics of these anticancer prodrugs.

¹ Supported in part by Grant CA-49248 from the NIH (to D. J. W.). Presented in part at the International Congress of Toxicology VII, Seattle, Washington, July, 1995.

² To whom requests for reprints should be addressed, at Division of Cell and Molecular Biology, Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215. Phone: (617) 353-7401; Fax: (617) 353-7404; E-mail: djw@bio.bu.edu.

Received 11/26/96. Accepted 3/24/97.

This article has been cited by other articles:

				B. Ning, S. Dial, Y. Sun, J. Wang, J. Yang, and L. Guo Systematic and Simultaneous Gene Profiling of 84 Drug-Metabolizing Genes in Primary Human Hepatocytes J Biomol Screen, March 1, 2008; 13(3): 194 - 201. [Abstract] [PDF]

				P. Afsharian, Y. Terelius, Z. Hassan, C. Nilsson, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on Cytochrome P450 2B in Rats Clin. Cancer Res., July 15, 2007; 13(14): 4218 - 4224. [Abstract] [Full Text] [PDF]

				D. Leveque and F. Jehl Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids J. Clin. Pharmacol., May 1, 2007; 47(5): 579 - 588. [Abstract] [Full Text] [PDF]

				T. K. L. Kiang, P. C. Ho, M. R. Anari, V. Tong, F. S. Abbott, and T. K. H. Chang Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype Toxicol. Sci., December 1, 2006; 94(2): 261 - 271. [Abstract] [Full Text] [PDF]

				P. Afsharian, Y. Terelius, S. Lundgren, and M. Hassan The Effect of Repeated Administration of Cyclophosphamide on CYP2B1 and 2B2 in Rat. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4460 - 4460. [Abstract]

				C.-S. Chen, Y. Jounaidi, and D. J. Waxman ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450 Drug Metab. Dispos., September 1, 2005; 33(9): 1261 - 1267. [Abstract] [Full Text] [PDF]

				Y. Chen, G. Kissling, M. Negishi, and J. A. Goldstein The Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Cross-Talk with Hepatic Nuclear Factor 4{alpha} to Synergistically Activate the Human CYP2C9 Promoter J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1125 - 1133. [Abstract] [Full Text] [PDF]

				A. DeMichele, R. Aplenc, J. Botbyl, T. Colligan, L. Wray, M. Klein-Cabral, A. Foulkes, P. Gimotty, J. Glick, B. Weber, et al. Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort J. Clin. Oncol., August 20, 2005; 23(24): 5552 - 5559. [Abstract] [Full Text] [PDF]

				D. Roymans, P. Annaert, J. Van Houdt, A. Weygers, J. Noukens, C. Sensenhauser, J. Silva, C. Van Looveren, J. Hendrickx, G. Mannens, et al. EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES Drug Metab. Dispos., July 1, 2005; 33(7): 1004 - 1016. [Abstract] [Full Text] [PDF]

				X. Zhuo, N. Zheng, C. A. Felix, and I. A. Blair KINETICS AND REGULATION OF CYTOCHROME P450-MEDIATED ETOPOSIDE METABOLISM Drug Metab. Dispos., September 1, 2004; 32(9): 993 - 1000. [Abstract] [Full Text] [PDF]

				H. Wang, S. Faucette, R. Moore, T. Sueyoshi, M. Negishi, and E. LeCluyse Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by Phenytoin J. Biol. Chem., July 9, 2004; 279(28): 29295 - 29301. [Abstract] [Full Text] [PDF]

				N. Zheng, C. A. Felix, S. Pang, R. Boston, P. Moate, J. Scavuzzo, and I. A. Blair Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide Clin. Cancer Res., May 1, 2004; 10(9): 2977 - 2985. [Abstract] [Full Text] [PDF]

				S. R. Faucette, H. Wang, G. A. Hamilton, S. L. Jolley, D. Gilbert, C. Lindley, B. Yan, M. Negishi, and E. L. LeCluyse REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS Drug Metab. Dispos., March 1, 2004; 32(3): 348 - 358. [Abstract] [Full Text] [PDF]

				S. M. Yule, L. Price, A. D. McMahon, A. D. J. Pearson, and A. V. Boddy Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma Clin. Cancer Res., January 15, 2004; 10(2): 455 - 460. [Abstract] [Full Text] [PDF]

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al. Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431. [Abstract] [Full Text] [PDF]

				R. J. Edwards, R. J. Price, P. S. Watts, A. B. Renwick, J. M. Tredger, A. R. Boobis, and B. G. Lake Induction of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices Drug Metab. Dispos., March 1, 2003; 31(3): 282 - 288. [Abstract] [Full Text] [PDF]

				T. K. H. Chang, S. M. Bandiera, and J. Chen Constitutive Androstane Receptor and Pregnane X Receptor Gene Expression in Human Liver: Interindividual Variability and Correlation with CYP2B6 mRNA Levels Drug Metab. Dispos., January 1, 2003; 31(1): 7 - 10. [Abstract] [Full Text] [PDF]

				T. A. Kocarek, M. S. Dahn, H. Cai, S. C. Strom, and N. A. Mercer-Haines Regulation of CYP2B6 and CYP3A Expression by Hydroxymethylglutaryl Coenzyme A Inhibitors in Primary Cultured Human Hepatocytes Drug Metab. Dispos., December 1, 2002; 30(12): 1400 - 1405. [Abstract] [Full Text] [PDF]

				B. Goodwin, E. Hodgson, D. J. D'Costa, G. R. Robertson, and C. Liddle Transcriptional Regulation of the Human CYP3A4 Gene by the Constitutive Androstane Receptor Mol. Pharmacol., August 1, 2002; 62(2): 359 - 365. [Abstract] [Full Text] [PDF]

				C. Lindley, G. Hamilton, J. S. McCune, S. Faucette, S. S. Shord, R. L. Hawke, H. Wang, D. Gilbert, S. Jolley, B. Yan, et al. The Effect of Cyclophosphamide with and without Dexamethasone on Cytochrome P450 3A4 and 2B6 in Human Hepatocytes Drug Metab. Dispos., July 1, 2002; 30(7): 814 - 822. [Abstract] [Full Text] [PDF]

				U. M. Kent, M. Aviram, M. Rosenblat, and P. F. Hollenberg The Licorice Root Derived Isoflavan Glabridin Inhibits the Activities of Human Cytochrome P450S 3A4, 2B6, and 2C9 Drug Metab. Dispos., June 1, 2002; 30(6): 709 - 715. [Abstract] [Full Text] [PDF]

				J. M. Rae, M. D. Johnson, M. E. Lippman, and D. A. Flockhart Rifampin Is a Selective, Pleiotropic Inducer of Drug Metabolism Genes in Human Hepatocytes: Studies with cDNA and Oligonucleotide Expression Arrays J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 849 - 857. [Abstract] [Full Text] [PDF]

				B. Goodwin, L. B. Moore, C. M. Stoltz, D. D. McKee, and S. A. Kliewer Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor Mol. Pharmacol., September 1, 2001; 60(3): 427 - 431. [Abstract] [Full Text] [PDF]

				S. R. Faucette, R. L. Hawke, S. S. Shord, E. L. Lecluyse, and C. M. Lindley Evaluation of the Contribution of Cytochrome P450 3A4 to Human Liver Microsomal Bupropion Hydroxylation Drug Metab. Dispos., August 1, 2001; 29(8): 1123 - 1129. [Abstract] [Full Text] [PDF]

				T. Kerbusch, R. A. A. Mathot, H. J. Keizer, G. P. Kaijser, J. H. M. Schellens, and J. H. Beijnen Influence of Dose and Infusion Duration on Pharmacokinetics of Ifosfamide and Metabolites Drug Metab. Dispos., July 1, 2001; 29(7): 967 - 975. [Abstract] [Full Text] [PDF]

				Y. Yanagihara, S. Kariya, M. Ohtani, K. Uchino, T. Aoyama, Y. Yamamura, and T. Iga Involvement of CYP2B6 in N-Demethylation of Ketamine in Human Liver Microsomes Drug Metab. Dispos., June 1, 2001; 29(6): 887 - 890. [Abstract] [Full Text]

				Y. Jounaidi and D. J. Waxman Frequent, Moderate-Dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer Gene Therapy Cancer Res., June 1, 2001; 61(11): 4437 - 4444. [Abstract] [Full Text] [PDF]

				S. Gerbal-Chaloin, J.-M. Pascussi, L. Pichard-Garcia, M. Daujat, F. Waechter, J.-M. Fabre, N. Carrère, and P. Maurel Induction of CYP2C Genes in Human Hepatocytes in Primary Culture Drug Metab. Dispos., March 1, 2001; 29(3): 242 - 251. [Abstract] [Full Text]

				S. R. Faucette, R. L. Hawke, E. L. Lecluyse, S. S. Shord, B. Yan, R. M. Laethem, and C. M. Lindley Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity Drug Metab. Dispos., October 1, 2000; 28(10): 1222 - 1230. [Abstract] [Full Text] [PDF]

				L. Pichard-Garcia, R. Hyland, J. Baulieu, J.-M. Fabre, A. Milton, and P. Maurel Human Hepatocytes in Primary Culture Predict Lack of Cytochrome P-450 3A4 Induction by Eletriptan In Vivo Drug Metab. Dispos., January 1, 2000; 28(1): 51 - 57. [Abstract] [Full Text]

				P. Roy, O. Tretyakov, J. Wright, and D. J. Waxman Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of R-Enantiomer Drug Metab. Dispos., November 1, 1999; 27(11): 1309 - 1318. [Abstract] [Full Text]

				V. Ramachandran, V. E. Kostrubsky, B. J. Komoroski, S. Zhang, K. Dorko, J. E. Esplen, S. C. Strom, and R. Venkataramanan Troglitazone Increases Cytochrome P-450 3A Protein and Activity in Primary Cultures of Human Hepatocytes Drug Metab. Dispos., October 1, 1999; 27(10): 1194 - 1199. [Abstract] [Full Text]

				V. E. Kostrubsky, V. Ramachandran, R. Venkataramanan, K. Dorko, J. E. Esplen, S. Zhang, J. F. Sinclair, S. A. Wrighton, and S. C. Strom The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450 Drug Metab. Dispos., August 1, 1999; 27(8): 887 - 894. [Abstract] [Full Text]

				P. Roy, L. J. Yu, C. L. Crespi, and D. J. Waxman Development of a Substrate-Activity Based Approach To Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles Drug Metab. Dispos., June 1, 1999; 27(6): 655 - 666. [Abstract] [Full Text]

				L. J. Yu, P. Drewes, K. Gustafsson, E. G. C. Brain, J. E. D. Hecht, and D. J. Waxman In Vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 928 - 937. [Abstract] [Full Text]

				C. Joqueviel, R. Martino, V. Gilard, M. Malet-Martino, P. Canal, and U. Niemeyer Urinary Excretion of Cyclophosphamide in Humans, Determined by Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy Drug Metab. Dispos., May 1, 1998; 26(5): 418 - 428. [Abstract] [Full Text]